Working… Menu

Safety and Acceptability of Carraguard™ Among HIV-negative Couples in Thailand

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00213057
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : August 14, 2017
Centers for Disease Control and Prevention
Ministry of Health, Thailand
Chiang Rai Public Health Office
Chiang Rai District Health Office
Chiang Rai Municipal Health Office
Chiang Rai Hospital
Bill and Melinda Gates Foundation
Information provided by:
Population Council

Brief Summary:

The primary aims of the study were to assess the safety and acceptability of Carraguard applied vaginally prior to sexual intercourse for six months in both women and men; and to examine several dimensions of acceptability. Secondary aims were to gauge reactions to a non-contraceptive microbicide, to assess use dynamics among Thai couples and to observe preliminary indications of sexually transmitted infections and reproductive tract infections averted.

The hypothesis was that Carraguard would cause little or no significant irritation, including lesions; and that women and men would find Carraguard acceptable.

Condition or disease Intervention/treatment Phase
HIV Infections Chlamydia Trachomatis Nesseria Gonorrhea Trichomonas Vaginitis Syphilis Drug: Carraguard (PC-515) Phase 1

Detailed Description:

Carraguard™ (PC-515), the Population Council's lead candidate microbicide, was tested in a triple-masked, randomized, placebo-controlled trial fielded in one site in Chiang Rai, northern Thailand. The primary aims of the study were to assess Carraguard's safety (toxicity) in both men and women - including signs of local irritation, such as itching or burning; changes in vaginal flora (women); and incidence of abnormal external genital, vaginal (women), and cervical findings (women) - when applied vaginally prior to intercourse for 6 months; to evaluate acceptability; to gauge men's and women's reactions to a non-contraceptive microbicide; and to explore microbicide use dynamics in a Thai population.

Secondary aims were to investigate sexually transmitted infections averted - including HIV, C. trachomatis, N. gonorrhoeae, T. vaginalis, and T. pallidum (preliminary indications) in men and women; bacterial vaginosis and candidaisis in women; and balanitis in men; and effect on cervical cytology.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 110 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: A Randomized, Placebo-controlled, Double-blind Trial to Assess Expanded Safety and Acceptability of Carraguard™ (PC-515) Vaginal Gel Among Heterosexual Couples in Chiang Rai
Actual Study Start Date : June 2001
Actual Study Completion Date : June 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Primary Outcome Measures :
  1. Safety (toxicity/local irritation): Genital exam and interview for signs and symptoms, 14-days after enrollment and monthly thereafter for 6 months; testing for bacterial vaginosis and candida (women) and balanitis (men) monthly.
  2. Acceptability: Interview about gel use to assess compliance (monthly) and acceptability (quarterly).

Secondary Outcome Measures :
  1. Preliminary effectiveness: Swabs taken from women an urine specimens collected from men to test for sexually transmitted infections - gonorrhea, chlamydia, trichomoniasis (monthly) and for genital ulcer disease, if ulceration was detected; blood drawn

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • · In good health,

    • Aged 18 years or older,
    • Resident for at least 1 year; planning to stay for at least 12 months,
    • HIV-seronegative and free of all other STD at initial screening exam,
    • No reported sex partners other than current partner for prior year and and not planning on having any other sex partners for the duration of the study,
    • Not using condoms routinely (>25% of the time) in the prior year
    • Willing and able to comply with the study protocol (including being tested for HIV, learning the results, agreeing to partner notification if a curable STD is diagnosed, and undergoing clinical evaluations),
    • Able to achieve a score of 80% or better on true-false test of key study concepts, and
    • Able to give informed consent.
    • Planning to have vaginal sexual intercourse together on average at least once per week during the next six months.

Exclusion Criteria:

  • · Pregnant or desire to become pregnant at time of study participation,

    • Delivered or aborted a pregnancy within the six weeks prior to screening,
    • Male sex partner known at enrollment to be HIV positive,
    • History of surgery on external genitalia, vagina or cervix in the six weeks prior to screening,
    • Recent history of non-menstrual vaginal bleeding with intercourse,
    • Clinically detectable genital abnormality (including presence of warts, or a structural or congenital abnormality),
    • Genital epithelial disruption; men/women with healed lesions (intact epithelium) will be eligible,
    • Untreated symptomatic bacterial vaginosis or candidiasis. Women with asymptomatic BV or yeast may be enrolled. Women with treated symptomatic BV or candidaisis may be enrolled once no longer symptomatic. Women with signs or laboratory evidence of BV or candidaisis may be enrolled if they are asymptomatic. Women with symptoms of vaginal infection may be enrolled only if their enrollment visit stat laboratory evaluation is negative for BV, candidaisis or trichomoniasis,
    • Presence of balanitis. Men with resolved balanitis (e.g. through treatment) will be eligible,
    • Abnormal Pap smear (Class II or above),
    • History of sensitivity/allergy to latex,
    • Concurrent participation in another trial of a vaginal product,
    • Injection of recreational drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00213057

Layout table for location information
Chiang Rai Health Club
Chiang Rai, Thailand, 57001
Sponsors and Collaborators
Population Council
Centers for Disease Control and Prevention
Ministry of Health, Thailand
Chiang Rai Public Health Office
Chiang Rai District Health Office
Chiang Rai Municipal Health Office
Chiang Rai Hospital
Bill and Melinda Gates Foundation
Layout table for investigator information
Principal Investigator: Kelly Blanchard, MSc Population Council

Layout table for additonal information Identifier: NCT00213057     History of Changes
Other Study ID Numbers: Population Council #270
CDC Protocol #2968
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: August 14, 2017
Last Verified: August 2017
Keywords provided by Population Council:
HIV prevention
sexually transmitted infections
sero-concordant couples
HIV Seronegativity
Additional relevant MeSH terms:
Layout table for MeSH terms
Trichomonas Vaginitis
Sexually Transmitted Diseases
Gram-Negative Bacterial Infections
Bacterial Infections
Sexually Transmitted Diseases, Bacterial
Genital Diseases, Male
Genital Diseases, Female
Neisseriaceae Infections
Vaginal Diseases
Treponemal Infections
Spirochaetales Infections
Trichomonas Infections
Protozoan Infections
Parasitic Diseases